Background: Young adults in the United States experience high rates of suicidal thoughts and behaviors (STB) but low engagement with traditional care, highlighting the need for accessible and scalable digital interventions. Self-guided digital safety planning interventions (SPIs) can expand access to support but introduce important decisions about what content to deliver, when systems should intervene, and how users retain control over system actions. Personalization, defined as system-initiated adaptation, and customization, defined as user-initiated control, may offer complementary approaches to these decisions. However, how they should be coordinated to preserve autonomy and reduce burden during periods of distress remains unclear. Objective: This study aims to identify key decision points in self-guided digital SPIs and characterize what, when, how, and by whom (system or user) safety planning functions should be controlled. We further examined how personalization and customization can jointly support autonomy, reduce burden, and promote safety. Methods: Nine young adults (ages 18‐24) with lived experience of suicidal thoughts and behaviors were recruited from an asynchronous remote community comprising individuals who had engaged with the Mental Health America (MHA) website. Participants completed semistructured individual interviews via Zoom. Three coders analyzed interview transcripts using codebook thematic analysis. One coder open-coded all transcripts to develop a preliminary codebook. Two additional coders then applied the codebook to overlapping transcripts, after which all coders revised the codebook and resolved discrepancies by consensus before coding the remaining transcripts. Themes were interpreted using the 5W1H (Who, What, Where, When, Why, and How) framework as an organizing lens for identifying and structuring decision points. Results: Participants identified 3 classes of decision points for self-guided digital SPIs: (1) system-level decisions about what content and actions are automatically provided; (2) user-level decisions about when and at what pace safety planning unfolds; and (3) shared decisions requiring coordination between users and the system. Participants favored system personalization of decision aids, coping suggestions, brainstorming prompts, example messages for contacting trusted others, affirmations, and relevant resources. In contrast, participants wanted control over the timing and pacing of safety planning and the representation and organization of their safety plans. Participants also emphasized that systems should obtain explicit permission before taking safety-relevant actions, such as contacting trusted others or connecting users with crisis counselors in response to increases in detected risk. Conclusions: Personalization and customization can function as complementary mechanisms for allocating decision authority within self-guided digital SPIs. The findings support a model of permissioned automation in which systems reduce cognitive and emotional burden through adaptive support while users retain control over safety-relevant actions. This decision-point framework provides a foundation for designing and evaluating self-guided suicide prevention technologies that balance adaptation, autonomy, and safety.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/b64b15554f504cb2b794b641aedec95d" />
STAT+: FDA adcomm members’ ties to industry under scrutiny
Good morning. Yesterday, we got the devastating news that STAT’s infectious disease correspondent, Helen Branswell, passed away. She was a reporter I always looked up to and was also an incredibly generous colleague. Please take the time to read this tribute to her.
The need-to-know this morning
- Liquidia and United Therapeutics reached a settlement agreement that resolves their ongoing patent litigation over Liquidia’s treatment for pulmonary arterial hypertension.
New trial to test effect of GLP-1s on social outcomes
Researchers in Pittsburgh are launching a novel type of GLP-1 trial — testing not only if the drug will help people with addiction, but also if it will help reduce recidivism while improving other employment, health, and housing outcomes.
The Center for Addiction Science, Policy and Research (CASPR), a non-profit organizing the effort, and the Allegheny County Department of Human Services are planning to launch the trial in early 2027. They will enroll up to 1,200 adults with alcohol use disorder, opioid use disorder, or both, who are also at high risk of criminal-justice involvement. Half will be randomly assigned to take Novo Nordisk’s Wegovy, according to a press release issued yesterday.
Translation, contextual adaptation, and preliminary evaluation of INCRESE-Norwegian Young
Emotional regulation ability and depressive symptoms among Chinese junior high school students: a cross-sectional analysis of the role of stress coping styles
Feasibility of Online and On-Site Physical Activity Delivery Among Older Adults: Mixed Methods Pilot Randomized Controlled Trial
X-Chromosome Gene Linked to Increased Autism Diagnosis in Males
Researchers at Baylor College of Medicine, the Duncan Neurological Research Institute (Duncan NRI) at Texas Children’s Hospital, and collaborating institutions have identified new genetic candidates that help explain why autism is diagnosed about four times more often in boys than it is in girls. The study, involving tests in induced pluripotent stem cell (iPSC)-derived neurons (iNeurons), revealed that small changes in the gene MECP2 on the X chromosome might help explain part of this difference.
Huda Zoghbi, MD, Distinguished Service Professor at Baylor, director of Duncan NRI, and a Howard Hughes Medical Institute investigator, is senior and corresponding author of the team’s published paper in The American Journal of Human Genetics, titled “A massively parallel reporter assay of MECP2 cis-regulatory elements reveals genetic candidates for male-biased autism.” In their paper, the team concluded, “These findings suggest noncoding MECP2 variants can cause idiopathic, male-biased autism and provide a framework for uncovering regulatory variants in other X chromosome neurodevelopmental genes that may contribute to autism’s missing heritability.”
“Autism is a common, heritable neurodevelopmental trait that affects how a person communicates, interacts with others, and experiences the world, and is characterized by altered social interactions and restricted, repetitive behaviors or interests,” Zoghbi explained. “It is diagnosed about four times more in male individuals than in female individuals, suggesting sex-specific factors may increase male vulnerability,” the researchers added in their paper.
In the current study, the researchers drew from their long experience with gene MECP2, which is on the X chromosome and has been associated with neurodevelopmental conditions, including autism. “We tested the idea that the predominance of autism in males could be explained in part by mild mutations in an X chromosome gene’s regulatory regions,” commented Rebecca Meyer-Schuman, PhD, a postdoctoral associate in the Zoghbi lab. “Females might be protected from such a mild mutation because of their second X chromosome, but males, who have only one copy, would be more vulnerable. The regulatory regions are like dials that control whether a gene will be expressed and by how much. And what better place to start looking at these regulatory regions than the gene MECP2, where brain health depends on how much of the gene is expressed, and where mutations can cause neurodevelopmental disorders that include autism.”
Previous murine studies by Zoghbi lab and others have taught researchers that MECP2 produces a Goldilocks protein, meaning that it must maintain a “just right” concentration or activity level for a healthy brain. Having too little—about 50% or less of the normal levels—leads to Rett syndrome, and having twice the normal levels causes a different neurodevelopmental condition called MECP2 duplication syndrome. “Both loss-of-function and gain-of-function variants lead to severe neurodevelopmental conditions—Rett syndrome (MIM: 312750) and MECP2 duplication syndrome (MDS; MIM: 300260[intellectual developmental disorder, X-linked, syndromic, Lubs type (MRXSL)]), respectively,” the authors commented. “Because MECP2 is on the X chromosome, hemizygous male individuals have a more severe phenotype than heterozygous female carriers with the same variant.”
Meyer-Schuman also noted, “Previous studies in mice also showed us that milder changes in MECP2 levels, for instance reducing the expression by 30% or increasing it by 50%, do not cause the more severe features of Rett syndrome or MECP2 duplication syndrome like seizures or motor problems, but lead to autism-like behaviors.”
For their current study the team used a massively parallel reporter assay (MPRA) to screen the regulatory regions of the MECP2 gene in induced pluripotent stem-cell (iPC)-derived neurons. “This allowed us to identify and manipulate the regulatory regions and determine what kinds of changes would alter their function,” Meyer-Schuman said. The researchers also screened MECP2 regulatory regions in autistic individuals and tested the genetic variants they identified using the MPRA assays.
“We identified two regulatory regions where male autistic individuals inherited a variant from their unaffected mother that altered regulatory activity,” Meyer-Schuman said. “One of these variants reduced MECP2 expression by approximately 30% in human neurons, a magnitude that produces social deficits, hyperactivity and anxiety-like characteristics in mice. As predicted by the mouse model, this individual was diagnosed with autism and ADHD but had none of the defining characteristics of Rett syndrome.”
In their paper, the authors commented that their work supports a broader hypothesis that altered dosage or expression of sex chromosome genes are a major source of the male bias observed in autism. Zoghbi added, “These findings, a result of integrating human and animal studies, suggest that MECP2 regulatory variants can contribute to male-biased autism and reveal just the tip of the iceberg, providing a framework for uncovering regulatory variants in other X chromosome neurodevelopmental genes that may contribute to autism’s missing heritability.”
The post X-Chromosome Gene Linked to Increased Autism Diagnosis in Males appeared first on GEN – Genetic Engineering and Biotechnology News.
Associations Between Daily EMA of Emotional Exhaustion and Monthly Burnout Symptoms During Work Reintegration: Longitudinal Multilevel Study
Background: Burnout is increasingly conceptualized as comprising both stable, slowly changing features and more dynamic, fluctuating features, with emotional exhaustion widely regarded as one of burnout’s core components. Traditionally, burnout has been assessed using retrospective self-report questionnaires, such as the Burnout Assessment Tool (BAT), administered at sporadic intervals. In contrast, ecological momentary assessment (EMA) enables high-frequency assessment of daily experiences while reducing recall bias. However, it is not well understood how EMA-based measures fluctuate and develop longitudinally within individuals or how they relate to retrospective burnout measures. Objective: This paper examined the relationship between 30-day aggregates of daily EMA-assessed emotional exhaustion, specifically the within-person mean level and variability (SD), and monthly burnout symptoms measured with the BAT. Methods: Eighteen participants undergoing work reintegration after stress- or burnout-related sick leave completed daily EMAs of emotional exhaustion (N=3157) and monthly BAT questionnaires over 6 months (N=94). For each monthly BAT assessment, EMA data from the preceding 30 days were aggregated into within-person mean and SD values. Linear mixed-effects models with random intercepts and time effects were fitted separately for each BAT subscale. Additionally, intraclass correlation coefficients (ICCs) were calculated to quantify the proportion of variance attributable to between-person differences. Results: ICCs indicated that a large proportion of variance in the BAT subscales was attributable to between-person differences, whereas daily EMA emotional exhaustion showed relatively greater within-person variability. Significant time-related changes were observed for the BAT subscales of Cognitive Impairment, Mental Distance, and Emotional Impairment. Within-person increases in the EMA mean of emotional exhaustion were significantly associated with higher scores on BAT Exhaustion (=0.073; =.001) and BAT Cognitive Impairment (=0.041; =.04). EMA-based variability (SD) and between-person mean levels were not significantly associated with any BAT subscale. Conditional values were high (0.667-0.777), whereas marginal values were modest (0.056-0.121). Consistent with the ICC findings, these results suggest that most explained variance in BAT scores reflects between-person differences and time-related changes, with EMA-derived predictors accounting for only a limited additional proportion of explained variance. Conclusions: EMA-based aggregates showed partial correspondence with monthly burnout scores. Within-person increases in mean daily emotional exhaustion were associated with higher subsequent scores on the BAT Exhaustion and Cognitive Impairment subscales, but EMA-based variability was not associated with any BAT subscale. Together with the ICC results, these findings suggest that EMA-based aggregates of emotional exhaustion can reflect short-term fluctuations and longer-term changes in symptom severity of exhaustion and cognitive impairment. Retrospective questionnaires remain useful for global symptom assessment or diagnoses at specific time points but appear less well suited for tracking within-person changes and supporting personalization. These results highlight the importance of aligning the choice of assessment with temporal and clinical goals.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/8e7551b589248f3c6b4937dab185362d" />

